158 related articles for article (PubMed ID: 30947538)
1. Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: Vitreous reflux and its amount.
Uyar E; Ulas F; Sahin S; Celebi S
Eur J Ophthalmol; 2019 Jul; 29(4):361-367. PubMed ID: 30947538
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
3. Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection.
Hong SW; Jee D
Eur J Ophthalmol; 2012; 22(4):615-9. PubMed ID: 22562298
[TBL] [Abstract][Full Text] [Related]
4. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
[TBL] [Abstract][Full Text] [Related]
5. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort.
Knecht PB; Michels S; Sturm V; Bosch MM; Menke MN
Retina; 2009 Sep; 29(8):1175-81. PubMed ID: 19734766
[TBL] [Abstract][Full Text] [Related]
6. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).
Sharei V; Höhn F; Köhler T; Hattenbach LO; Mirshahi A
Eur J Ophthalmol; 2010; 20(1):174-9. PubMed ID: 19927267
[TBL] [Abstract][Full Text] [Related]
7. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
Omay E; Elgin U; Sen E; Yilmazbas P
Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
[TBL] [Abstract][Full Text] [Related]
8. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
9. Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?
Uyar E; Ulaş F; Alkan Y
Curr Eye Res; 2021 Feb; 46(2):248-254. PubMed ID: 32635750
[TBL] [Abstract][Full Text] [Related]
10. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
11. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique.
Kim KS; Jee D
Jpn J Ophthalmol; 2011 Nov; 55(6):632-7. PubMed ID: 21947489
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections.
Shoeibi N; Ghosi Z; Jafari H; Omidtabrizi A
Int Ophthalmol; 2021 Mar; 41(3):1081-1090. PubMed ID: 33389369
[TBL] [Abstract][Full Text] [Related]
13. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
14. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide.
Benz MS; Albini TA; Holz ER; Lakhanpal RR; Westfall AC; Iyer MN; Carvounis PE
Ophthalmology; 2006 Jul; 113(7):1174-8. PubMed ID: 16647122
[TBL] [Abstract][Full Text] [Related]
15. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
16. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
17. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application.
Höhn F; Mirshahi A
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1371-5. PubMed ID: 20407785
[TBL] [Abstract][Full Text] [Related]
18. Vitreous incarceration after ranibizumab injection: an ultrasound biomicroscopy study.
Helvaci S; Sahinoglu-Keskek N; Kiziloglu M; Oksuz H; Cevher S
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):471-4. PubMed ID: 25932725
[TBL] [Abstract][Full Text] [Related]
19. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
